Glutathione S-transferase (GST) enzymes protect cells against xenobiotics and oxidative stress products through an electrophilic conjugation process. We investigated the theta (GSTT1) and mu (GSTM1) null genotypes in a group of leukopenic subjects and normal subjects from Northeast Brazil, evaluating their use as biomarkers of susceptibility for developing leukopenia. In a sample-based case-control study, we analysed white blood cell (WBC) counts and GSTT1 and GSTM1 genotypes. A total of 278 subjects were analysed: 91 with leukopenia and 187 controls. GSTT1 null genotype conferred a 5.92-fold risk for occurrence of leukopenia [odds ratios (OR) = 5.92, CI MLE : 1.64-26.72, P MLE = 0.002] and a 3.90-fold risk of neutropenia (OR = 3.90; CI MLE : 1.05-13.66; P MLE = 0.02), while GSTM1 null genotype conferred a 1.78-fold risk for leukopenia (OR = 1.75; CI MLE : 1.04-3.06, P MLE = 0.017) and no risk of neutropenia (OR = 1.71; CI MLE : 0.88-3.35; P MLE = 0.06). The GSTT1, but not the GSTM1 null genotype, was found to be associated with leukopenia and neutropenia. More cellular and molecular studies are needed to evaluate the existence of genotype interactions, and to confirm the appropriateness of using the GSTT1 and/or GSTM1 null genotypes as biomarkers of susceptibility to white blood-cell deficiencies.
S U M M A R Y
Glutathione S-transferase (GST) enzymes protect cells against xenobiotics and oxidative stress products through an electrophilic conjugation process. We investigated the theta (GSTT1) and mu (GSTM1) null genotypes in a group of leukopenic subjects and normal subjects from Northeast Brazil, evaluating their use as biomarkers of susceptibility for developing leukopenia. In a sample-based case-control study, we analysed white blood cell (WBC) counts and GSTT1 and GSTM1 genotypes. A total of 278 subjects were analysed: 91 with leukopenia and 187 controls. GSTT1 null genotype conferred a 5.92-fold risk for occurrence of leukopenia [odds ratios (OR) = 5.92, CI MLE : 1.64-26.72, P MLE = 0.002] and a 3.90-fold risk of neutropenia (OR = 3.90; CI MLE : 1.05-13.66; P MLE = 0.02), while GSTM1 null genotype conferred a 1.78-fold risk for leukopenia (OR = 1.75; CI MLE : 1.04-3.06, P MLE = 0.017) and no risk of neutropenia (OR = 1.71; CI MLE : 0.88-3.35; P MLE = 0.06). The GSTT1, but not the GSTM1 null genotype, was found to be associated with leukopenia and neutropenia. More cellular and molecular studies are needed to evaluate the existence of genotype interactions, and to confirm the appropriateness of using the GSTT1 and/or GSTM1 null genotypes as biomarkers of susceptibility to white blood-cell deficiencies.
I N T R O D U C T IO N
Leukocytes play an important role in defending the body against xenobiotics through phagocytosis and antibody production. Phagocytes are classified as either granulocytes (e.g. neutrophils, eosinophils, and basophils) or as monocytes/macrophages (Bondurant & Koury, 1998) . Exposure to substances which are toxic to bone marrow can result in pancytopenia, a decrease in the circulating number of all three types of blood elements: red blood cells, white blood cells (WBC) and platelets. The diagnosis of this condition is based on peripheral blood cell counts of these elements. In early stages, decreased WBC count can occur in the absence of other characteristic symptoms such as neutropenia or granulocytopenia (Gay & Athens, 1998) .
Glutathione is found in virtually all cell types, where it participates in intracellular oxidant defense mechanisms and serves as a key substrate for several intermediate steps of biological metabolism (Mannervik, 1985) . Glutathione S-Transferase (GST) gene family comprises 16 genes in six subfamilies, the alpha (GSTA); mu (GSTM); omega (GSTO); pi (GSTP); theta (GSTT), and zeta (GSTZ) (Mannervik et al., 1992; Nebert & Vasiliou, 2004 ) that belong to a family of intracellular enzymes that play a major role in the cellular detoxification of electrophilic compounds of endogenous and exogenous origin.
Genetic polymorphisms of GST have been described in several populations and the GSTM1 absence is associated with an increased risk of developing cystic fibrosis, smoking-induced lung and bladder cancers and childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (Pakakasama et al., 2005; Aydin-Sayitoglu et al., 2006) , and some multifactorial diseases (Baranov et al., 1996) . The absence of the GSTT1 gene is associated with a high risk of myelodysplastic syndromes (Chen et al., 1996) and ALL (Krajinovic et al., 1999) . These findings are important, as GSTT1 null genotype carriers probably have a reduced ability to detoxify metabolites of carcinogens such as 1,3-butadiene (Wiencke et al., 1995) , methyl bromide and ethylene oxide ; in addition, GSTM1 gene products have been shown to detoxify carcinogens such as 1,2-epoxy-3-butene (Sasiadek et al., 1999) .
The GSTA, found predominantly in the liver, has been associated with a reduction of lipid hydroperoxides by glutathione peroxidase activity, and is commonly considered to be a marker of hepatocellular damage (Singhal et al., 1992; Nelson et al., 1995a,b; Coles & Kadlubar, 2005) . The GSTP enzyme has been associated with resistance to several anti-cancer drugs; studies have shown that tumor cells from different types of cancers over-express this isoenzyme, a discovery which has driven efforts to find a selective inhibitor of this GST class (Oakley et al., 1997; Lecomte et al., 2006) .
The GSTO enzyme has been found to play a role in apoptosis and be associated with age (Wang et al., 2005) and the GSTZ class was recently found and related to the catalyse and oxygenation of diclhoroacetic acid and other alpha-haloacids (Tong, Board & Anders, 1998; Board & Anders, 2005) . Thus, the presence of the functional GST gene has an important role in cellular defense against toxic factors. Here, we test the hypothesis that the presence of the GSTT1 and/or GSTM1 null genotype increases the risk of developing leukopenia. We focused on the GSTM and GSTT subtypes because these are most closely associated with hematologic and neoplastic diseases.
M A T E RI A L S A N D M E T H O D S
This study was conducted in the city of Salvador, which has the highest rate of race admixture in Brazil. A subset of those blood samples drawn at a clinical laboratory during a two-month period (May and June of 2001) was selected and data from the patients who provided the blood samples were subsequently collected. This laboratory, LABCHECAP, is a clinical laboratory where a diverse socio-economic cross-section of Salvador undergoes routine clinical laboratory evaluations. All blood samples collected during the 2-month time period that satisfied the definition of leukopenia (WBC<4.0 · 10 9 /L) were selected for inclusion as cases (91 samples). Patients with a history of viral infection during the two weeks preceding blood collection were excluded. For each case, two blood samples collected during the same period which had normal leukocyte counts (i.e. between WBC4.0 · 10 9 /L and 10.0 · 11 9 /L 3 ) were selected as controls, and were matched to cases according to age (±5 years), gender, and racial ancestry. The molecular characterization of GSTT1 and GSTM1 genotypes was performed at the Laboratory of Molecular Pathology and Biology, Gonçalo Moniz Research Center (a regional branch of the Oswaldo Cruz Foundation -FIOCRUZ). The subjects were between 1 and 89 years of age (median = 40.0; mean = 38.9; standard deviation = 17.6). Informed consent was obtained from all individuals or official responsible prior to enrollment. The study protocol was submitted to and approved by the Oswaldo Cruz Research Foundation's human research ethics committee.
Five millilitres of peripheral blood was obtained from each individual for haematologic analysis and DNA extraction. All blood samples were anti-coagulated with EDTA. Haematologic data were obtained with an automated cell counter (Celldyn 3000 -Abbott) and by standard procedures. DNA was isolated from leukocytes with a GFX genomic blood DNA purification kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to the manufacturer's instructions. The GSTT1 and GSTM1 genotypes were determined by a multiplex PCR technique, using bglobin amplification as an internal reaction control, as described previously (Baranov et al., 1996; Krajinovic et al., 1999) . Each set of reactions also included negative controls to verify the purity of all reagents. Briefly, the PCR buffer reaction mix contained TrisHCl 10 mmole/l (pH 8.4); KCl 75 mmole : l; MgCl 2 3.5 mmole/l; dNTP 200 lmole/l each; 2.5 U of Taq DNA polymerase (Gibco-BRL Life Technologies, Grand Island, NY, USA); 25 pmol of each specific primer, and approximately 0.5 ng of DNA sample. All reactions were carried out in a Perkin-Elmer Thermocycler model 2400 (Perkin Elmer Inc., Waltham, MA, USA). The PCR reaction mix was heated at 94°C for 10 min, followed by 35 cycles of denaturation (94°C for 45 s), annealing (58°C for 45 s), and extension (72°C for 1 min 30 s). After cycling, the tubes were initially kept at 72°C for 10 min, then cooled to 4°C and analysed by gel electrophoresis (1% agarose in TAE 1· stained with ethidium bromide) and UV visualized. 
Statistical analysis
Maximum likelihood (MLE) estimates of odds ratios (OR) and their respective confidence intervals were used to measure the strength of association between the presence of GST null genotypes (GSTT1 and GSTM1) and leukopenia/neutropenia in the case-control analysis. The MLE method or maximum likelihood estimation was used because only a limited number of leukopenic subjects, but not the entire population, was included in the in the study. The sample mean was then the maximum likelihood estimator of the population mean, and the sample variation was a close approximation to the maximum likelihood estimator of the population variance. First, the crude risk of leukopenia and/or neutropenia associated with the presence of each null genotype was calculated. Stratified analyses were then conducted to evaluate the presence of effect modification between the two null genotypes (i.e. to evaluate whether the risk of leukopenia/neutropenia associated with the deletion of one gene was influenced by deletion of the other gene). All measures of association were 
R E S U L T S
Of the 278 individuals who were recruited into the study, 91 were leukopenic subjects (WBC<4.0 · 10 9 /l) and 187 had normal WBC counts (WBC 4.0 · 10 9 /l and <11.0 · 10 9 /l). Analysis of granulocytic neutrophil counts demonstrated that 53.8% of leucopenic subjects had neutrophil counts less then 1.5 · 10 9 /l (indicating the presence of neutropenia). All subjects studied were classified into one of six groups, according to their GSTT1 and GSTM1 genotypes: 137 (49.3%) had normal GST genotypes for both genes (group 1); 100 (36.0%) had GSTM1 null genotype and normal GSTT1 gene (group 2); 8 (2.9%) had normal GSTM1 and GSTT1 null genotype (group 3); 6 (2.2%) had null genotype for both genes (group 4); 11 (3.95%) were found to have a GSTM1 null genotype and a smaller GSTT1 fragment that we characterized as a partial GSTT1 deletion (group 5); and 16 (5.75%) had a normal GSTM1 genotype and partial GSTT1 deletion (group 6). The distribution of GST genotypes in the leukopenic subjects and normal WBC-count groups is summarized in Table 1 .
Ten leucopenic subjects had GSTT1 null genotype and 70 leukopenic subjects had normal GSTT1 genotype. Four subjects with normal WBC count had GSTT1 null genotype, and 167 had normal WBC count and normal GSTT1 genotype. In contrast, 40 leukopenic subjects had GSTM1 null genotype and 40 leukopenic subjects had normal GSTM1 genotype. Sixty-six subjects had normal WBC count and GSTM1 null genotype and 105 had normal WBC count and normal GSTM1 genotype. The leukopenic subjects and normal WBC count groups were found to have similar age and gender distributions, as shown in Table 2 .
The case-control study revealed that both GSTT1 and GSTM1 null genotypes were associated with white blood-cell deficiencies. Comparison of the distribution of leukopenia in groups 3 and 4 (GSTT1 null genotype) with that in groups 1 and 2 (GSTT1 normal) showed that the GSTT1 null genotype conferred a 5.92-fold risk of leukopenia (OR = 5.92, CI MLE : 1.64-26.72, P MLE = 0.002) and a 3.90-fold risk of neutropenia (OR = 3.90; CI MLE : 1.05-13.66; P MLE = 0.02). Partial deletion of the GSTT1 gene was not found to be significantly associated with leukopenia (OR = 1.64; CI MLE : 0.65-3.98, P MLE = 0.16) or with neutropenia (OR = 1.19; CI MLE : 0.33-3.49; P MLE = 0.46), as determined by comparing the distributions of leukopenia and neutropenia in groups 4 and 5 with the distribution in groups 1 and 2 (Table 3) . As a result, the individuals with partial deletion of GSTT1 were not included in the calculation of the risk associated with complete deletion of GSTT1.
We also found evidence of an association between the presence of GSTM1 deletion and leukopenia (OR = 1.78; CI MLE : 1.04-3.06; P MLE = 0.017), but not with neutropenia (OR = 1.71, CI MLE : 0.88-3.35; P MLE = 0.06) ( Table 3) .
The stratified analysis indicated that the risk of white blood-cell deficiencies associated with GSTT1 deletion could depend on the GSTM1 genotype (i.e. that GSTM1 genotype is potentially an effect modifier of the relationship between GSTT1 deletion and WBC deficiency), although the associated confidence intervals were too wide to draw definitive conclusions. Individuals with both GSTM1 and GSTT1 deletion appeared to have a smaller risk of leukopenia (OR = 3.51; CI MLE = 0.48-40.61; P MLE = 0.14) and neutropenia (OR = 1.87, CI MLE : 0.16-14.09; P MLE = 0.39) relative to the crude risk associated with GSTT1 deletion, while individuals with GSTM1 normal genotype and GSTT1 deletion appeared to have increased risk of both leukopenia (OR = 8.92; CI MLE : 1.51-94.41; P MLE = 0.006) and neutropenia (OR = 6.90, CI MLE : 1.17-40.85; P MLE = 0.02) relative to the crude risks associated with GSTT1 deletion. The risk of leukopenia associated with GSTM1 deletion appeared to not vary according to GSTT1 genotype: individuals with partial GSTT1 deletion appeared to have not risk for leukopenia (OR = 4.90; CI MLE : 0.77-38.49; P MLE = 0.05) and neutropenia (OR = 2.53, CI MLE : 0.24-36.44; P MLE = 0.31), followed by individuals with normal GSTT1 (leukopenia: OR = 3.11; CI MLE : 0.93-3.11; P MLE = 0.04) (neutropenia OR = 1.87, CI MLE : 0.88-4.04; P MLE = 0.055) and finally by those with complete GSTT1 deletion (leukopenia OR = 0.69; CI MLE : 0.03-13.3; P MLE = 0.59) (neutropenia OR = 0.53; CI MLE : 0.03-6.71; P MLE = 0.47); once again, however, the wide confidence intervals prevent us from drawing definitive conclusions from this stratified analysis.
D I S C U S S I O N
Our results suggest that individuals with GSTT1 null genotype have a higher risk of both leukopenia and neutropenia. Furthermore, the results of the stratified analyses suggest that there is potential for genotype interaction, although the extremely wide confidence intervals prevented us from drawing definitive conclusions. The fact that the risk of leukopenia and neutropenia associated with both GSTT1 and GSTM1 null genotypes appears to be greater when the other genotype was normal than when both genotypes were null is an apparently counter-intuitive finding, and merits further investigation. Unfortunately, there was not a prior study that estimates frequencies of GSTT1 and GSTM1 deletions in this population and in closed ethnic population groups and thus unable us to calculate the sample size that would have been required to adequately evaluate potential interactions between the two genotypes. Furthermore, the observed frequency of GSTT1 was much lower than was previously described in others Brazilian groups (Arruda et al., 1998 , Gattá s et al., 2004 , which also contributed to the wide confidence intervals.
The identification of a partial GSTT1 deletion in this analysis was unexpected. As a result, we were also unable to choose, a priori, an appropriate sample size that was adequate for determining whether or not this partial deletion is associated with excess risk of leukopenia. However, this partial deletion did not appear to confer excess risk for white blood cell deficiencies directly.
Several studies have been conducted to investigate whether the deletion of GST genes may be a suitable genetic marker of high risk for developing a variety of diseases (Warwick et al., 1994; Nelson et al., 1995a,b; Wiencke et al., 1995; Nedelcheva Kristensen et al., Ye & Song., 2005) . However, this hypothesis is controversial, and this discrepancy has been attributed to an uneven distribution of enzyme activity in several ethnic groups (Nelson et al., 1995a,b; Atoyebi et al., 1997; Basu et al., 1997; Arruda et al., 1998; Krajinovic et al., 1999) . Chen et al. (1997) found a higher frequency of GSTT1 and GSTM1 deletion in black children with ALL (8 of 34 or 23.5%) than in black controls (3.9%) (P = 0.0005). The authors suggest that the GST genotype, coupled with unidentified additional risk factors, may play a role in childhood ALL in African-Americans. Xiao et al. (2008) described that a complete remission rate was higher in AML patients group with normal GSTM1 and GSTT1genes than the GSTM1(OR = 1.88; P = 0.03) and GSTT1 (OR = 2.20; P = 0.02) null genotypes. Our group (Souza et al., 2008) found a higher frequency of GSTM1/GSTT1 null genotypes among Acute promyelocytic leukemia patients (OR = 3.61; P = 0.002). Our finding of a high risk of leukopenia in GSTT1 null genotypes in this racially mixed population (Azevedo et al., 1980; Gonçalves, Souza & Moura Neto, 2000) could be due to a genetic predisposition for low absolute leukocyte counts, such as those described in Ethiopian Jews (Berrebi, Melamed & Van Dam, 1987) and black Africans (Shaper & Lewis, 1971) . However, lower counts are less evident in black Americans (Orfanakis et al., 1970) and in Africans who consume Western diets (Bain & England, 1975) . Alterations in the total number of leukocytes and their relative proportions are known to be significant measures of physiologic reaction to noxious agents (Gay & Athens, 1998) . As a result, the relationship between low leukocyte count, ethnicity and GST null genotype should be investigated more closely. We also believe that studies of GST deletion in leukopenic subjects with xenobiotic exposure history could clarify the observed 5.92-fold increased risk of leukopenia associated with a GSTT1 null genotype presence. Several in vitro experiments have shown differences in cellular responses to chemical exposition to benzene and hydroquinone (Gut et al., 1996; Hazel et al., 1996) . We are not aware of any studies that have attempted to determine the risk of leukopenia associated with GST null genotypes. More detailed studies need to be performed to clarify the value of using null genotypes as markers for leukopenia risk, and to evaluate whether the partial GSTT1 deletion identified here is unique to Salvador's population. 
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